WilmerHale Represents Thermo Fisher in its €1.2 Billion Registered Public Offering of Senior Notes

WilmerHale Represents Thermo Fisher in its €1.2 Billion Registered Public Offering of Senior Notes

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

WilmerHale represented Thermo Fisher Scientific Inc., a multinational biotechnology product development company, in its public offering of €600 million aggregate principal amount of 1.750% Senior Notes due 2027, priced at 99.190% of principal, and €600 million aggregate principal amount of 2.375% Senior Notes due 2032, priced at 98.940% of principal. The net proceeds of the offering will be used, with the proceeds of the US offering described above, to pay a portion of the purchase price of the previously announced acquisition of QIAGEN N.V. and for general corporate purposes. The offering priced on March 30, 2020 and closed on April 2, 2020.

The team consisted of Erika Robinson, Justin Ochs, Knute Salhus, Julie Hogan Rodgers, Alan Wilson, Jenny Moore and Alex Bernstein.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel